CLINICAL_TRIALS
trial_result
· 2020-08-11
Clinical Trial Update: BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) [Phase 1]
Summary
A Phase 1 dose-escalation trial of BI 836826 in patients with relapsed or refractory non-Hodgkin lymphoma has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Lymphoma, Non-Hodgkin | Phase 1 | Status: COMPLETED | Results posted: 2020-08-11